explore -WSS

explore

author：focus 2025-09-28 00:52:29 - browse：119

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Drug repurposing or repositioning? The language matters
Next article： What the US credit downgrade means for the economy, your finances

explore

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Mitch McConnell episode has important public health takeaway

AstraZeneca stays mum on Medicare drug pricing negotiations

Cano Health’s bankruptcy is a warning for Medicare Advantage

No plane should take off without an EpiPen onboard

leisure time

explore

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amazon expands telehealth clinic nationwide

As demand for Covid shots wanes, Moderna seeks its next success

The high personal cost of affirmative action for Black doctors

Apple is now the first public company to be valued at $3 trillion

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

How to save PrEP access — and even expand it

Readout Newsletter: Amgen, Regeneron, BGI Group and more

BioMarin wins approval for gene therapy to treat hemophilia A

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

leisure time

National panel will explore requiring free Covid tests

The Biogen Aduhelm mess could happen again

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Sage hopes for a blockbuster in antidepressant now before FDA

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Sage hopes for a blockbuster in antidepressant now before FDA

leisure time

explore

leisure time

focus